KAMADA LTD

CEO London Amir’s recent option buy at KAMADA signals insider confidence in the company’s plasma‑therapeutic pipeline and long‑term prospects.

Inside Kamada’s latest insider buying, VP Boris Gorelik’s 15,000-option purchase signals bullish confidence amid a rising dividend and pipeline excitement.

Kamadas insider buy by Livneh Nir signals optimism amid 99.6% slump, hinting potential rebound as plasma therapeutics reach clinical milestones.